New research suggests that people who stop using new GLP-1 drugs like semaglutide or tirzepatide can put back on lost weight much more quickly than those who halt conventional lifestyle plans.
Research printed in a leading medical journal demonstrates that while overweight people often shed substantial amounts of their total mass while undergoing treatment, the mass is regained at an average rate of nearly a kilo each month after stopping.
"People using these medications must be informed of the potential of rapid weight regain when the treatment is stopped," warns researcher Dr. Susan Jebb.
Such speed of recovery implies a reversion to original weight in about 18 months.
Comparing Therapies
The research, which reviewed dozens of studies involving thousands of patients, contrasted the results of these new drugs with older methods.
Researchers note that individuals who lose weight through lifestyle changes alone generally have a less rapid creep back—perhaps 100 grams monthly—after stopping.
The Reason for the Quick Rebound
Nutrition scientists believe the way of the jabs explains the heightened regain.
GLP-1 drugs imitate a body's own chemical called GLP-1, which moderates hunger.
"Sustained high doses of GLP-1 concentrations far above than normal could lead to the body to generate a reduced amount of its endogenous hormone, and may also reduce responsiveness to its actions," explained Dr. Adam Collins, a dietetics specialist.
"Discontinuation of this GLP-1 'fix' leads to appetite is unsuppressed, making excessive eating a significant risk."
A Lifelong Condition?
Health authorities suggest the injections for individuals with weight-linked health risks, alongside recommended lifestyle changes.
Many experts contend that, considering the significant potential of relapse, the therapy might need to be long-term.
This perspective is supported by pharmaceutical companies, who state that the findings "underscore the chronic character of excess weight," comparing it to managing diseases like high blood pressure.
User Testimonies
Individuals who have discontinued the jabs report a powerful resurgence of appetite.
"It was like a switch flipping and I was suddenly starving," recalled an individual.
This challenge is exacerbated if patients have not adopted lasting dietary or behavioural changes during therapy.
Growing Adoption
Recent estimates suggest that millions of people in the UK have tried these injections in the last 12 months, with desire being substantial.
- Use is more common among females than males.
- The middle-aged demographic shows the highest level of interest.
- Many access the medications through private healthcare rather than the NHS.
Ultimately, experts caution that while the jabs are potent tools for shedding pounds, they are not a standalone fix and long-term success likely depends on integrated lifestyle support.
